BE2015C027I2 - - Google Patents

Download PDF

Info

Publication number: BE2015C027I2
Authority: BE; Belgium
Prior art keywords: antibodies; kdr; single chain; chain antibodies; triabodies
Prior art date: 2002-03-04

Application number

BE2015C027C

Other languages

English (en)

Original Assignee

Imclone Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-04

Filing date

2015-05-06

Publication date

2022-05-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27805075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2015C027(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-05-06 Application filed by Imclone Llc filed Critical Imclone Llc

2022-05-19 Publication of BE2015C027I2 publication Critical patent/BE2015C027I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Oncology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

BE2015C027C 2002-03-04 2015-05-06 BE2015C027I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36178302P	2002-03-04	2002-03-04
EP03711375A EP1487856B1 (fr)	2002-03-04	2003-03-04	Anticorps humains specifiques de kdr et leurs utilisations

Publications (1)

Publication Number	Publication Date
BE2015C027I2 true BE2015C027I2 (fr)	2022-05-19

Family

ID=27805075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2015C027C BE2015C027I2 (fr)	2002-03-04	2015-05-06

Country Status (17)

Country	Link
US (2)	US7498414B2 (fr)
EP (3)	EP2298346A3 (fr)
JP (3)	JP2005526506A (fr)
AT (2)	ATE475431T1 (fr)
AU (1)	AU2003213687A1 (fr)
BE (1)	BE2015C027I2 (fr)
CA (1)	CA2478169C (fr)
CY (3)	CY1111141T1 (fr)
DE (1)	DE60333554D1 (fr)
DK (2)	DK1916001T3 (fr)
ES (2)	ES2347543T3 (fr)
FR (1)	FR15C0034I2 (fr)
HU (1)	HUS1500025I1 (fr)
LU (1)	LU92710I2 (fr)
PT (2)	PT1487856E (fr)
SI (2)	SI1487856T1 (fr)
WO (1)	WO2003075840A2 (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60333554D1 (de) *	2002-03-04	2010-09-09	Imclone Llc	Kdr-spezifische humane antikörper und deren anwendung
US7638605B2 (en)	2003-05-01	2009-12-29	ImClone, LLC	Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1711196A4 (fr)	2003-12-05	2011-09-14	Bristol Myers Squibb Co	Inhibiteurs des recepteurs du facteur de croissance endothelial vasculaire de type 2
KR101333449B1 (ko) *	2003-12-10	2013-11-26	메다렉스, 엘.엘.시.	Ｉｐ―１０ 항체 및 그의 용도
ES2533492T3 (es) *	2004-02-06	2015-04-10	University Of Massachusetts	Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos
MXPA06010715A (es)	2004-03-19	2007-05-23	Imclone Systems Inc	Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
JP4633788B2 (ja)	2004-04-13	2011-02-16	エフ．ホフマン−ラロシュアーゲー	抗ｐ−セレクチン抗体
CA2594356C (fr)	2005-01-05	2018-07-17	F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H.	Domaines immunoglobuline synthetiques a proprietes de liaison elabores dans des regions de la molecule differentes des regions de determination de complementarite
US20060234941A1 (en)	2005-04-15	2006-10-19	The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services	Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
RU2502523C2 (ru)	2005-06-17	2013-12-27	Имклоун Элэлси	АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ
EP1902145A4 (fr) *	2005-07-13	2010-04-14	Beth Israel Hospital	Méthodes de diagnostic et de traitement d'une réponse inflammatoire
EP3168234A1 (fr) *	2005-12-15	2017-05-17	Medimmune Limited	Combinaison d'un antagoniste de l'angiopoietine 2 et d'un antagoniste du vegf-a et/ou du kdr et/ou du fltl pour le traitement du cancer
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
JP5537946B2 (ja)	2006-11-22	2014-07-02	ブリストル−マイヤーズスクイブカンパニー	Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
CA2687633A1 (fr) *	2007-05-24	2008-11-27	Ablynx N.V.	Sequences d'acides amines dirigees contre les recepteurs des facteurs de croissance et polypeptides renfermant ces dernieres, destines au traitement de maladies et affections associees aux facteurs de croissance et a leurs recepteurs
KR100883430B1 (ko) *	2007-06-13	2009-02-12	한국생명공학연구원	혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US8921279B2 (en)	2007-06-26	2014-12-30	F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H	Display of binding agents
US10214588B2 (en) *	2007-07-03	2019-02-26	Ablynx N.V.	Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
JP2010534469A (ja) *	2007-07-25	2010-11-11	アストラゼネカアクチボラグ	Ｋｄｒ指向性標的化結合物質およびその使用
UY31478A1 (es)	2007-11-21	2009-07-17		Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
MX2010008874A (es)	2008-02-14	2010-09-22	Bristol Myers Squibb Co	Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
EP2113255A1 (fr)	2008-05-02	2009-11-04	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Immunoglobuline cytotoxique
EP2799448A1 (fr)	2008-05-22	2014-11-05	Bristol-Myers Squibb Company	Protéines de domaine d'échafaudage à base de fribronectine multivalente
TWI496582B (zh)	2008-11-24	2015-08-21	必治妥美雅史谷比公司	雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
KR101224468B1 (ko)	2009-05-20	2013-01-23	주식회사 파멥신	신규한 형태의 이중표적항체 및 그 용도
US20120183547A1 (en) *	2009-05-27	2012-07-19	Mount Sinai School Of Medicine	Compositions and methods comprising vegfr-2 and vegfr-3 antagonists for the treatment of metastatic disease
US8465743B2 (en)	2009-10-01	2013-06-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011090648A2 (fr) *	2009-12-29	2011-07-28	Yale University	Inhibiteurs des récepteurs du facteur de croissance de l'endothélium vasculaire (vegf) et procédés pour les utiliser
US9328162B2 (en)	2010-02-25	2016-05-03	Schepens Eye Research Institute	Therapeutic compositions for the treatment of dry eye disease
WO2011150133A2 (fr)	2010-05-26	2011-12-01	Bristol-Myers Squibb Company	Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
WO2012019168A2 (fr)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Acides nucléiques modifiés et leurs procédés d'utilisation
ES3005233T3 (en)	2010-10-01	2025-03-14	Modernatx Inc	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (de)	2011-03-31	2021-09-30	Modernatx, Inc.	Freisetzung und formulierung von manipulierten nukleinsäuren
WO2012138997A1 (fr)	2011-04-07	2012-10-11	Amgen Inc.	Nouvelles protéines de liaison d'egfr
SG10201604493TA (en)	2011-06-02	2016-07-28	Dyax Corp	Fc RECEPTOR BINDING PROTEINS
HK1199883A1 (en)	2011-08-26	2015-07-24	Merrimack Pharmaceuticals, Inc.	Tandem fc bispecific antibodies
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru)	2011-10-03	2018-04-02	Модерна Терапьютикс, Инк.	Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
RU2014122184A (ru)	2011-11-02	2015-12-10	Апексиджен, Инк.	Антитела к kdr и способы их применения
AU2012352180A1 (en)	2011-12-16	2014-07-31	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151663A1 (fr)	2012-04-02	2013-10-10	modeRNA Therapeutics	Polynucléotides modifiés pour la production de protéines membranaires
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
EP2903647B1 (fr) *	2012-10-05	2020-01-01	Kadmon Corporation, LLC	Anticorps humains anti-vegfr-2/kdr
CN104870476B (zh)	2012-11-21	2018-04-13	药物抗体公司	靶向vegfr‑2和dll4的双靶向抗体及包含它的药物组合物
HRP20220607T1 (hr)	2012-11-26	2022-06-24	Modernatx, Inc.	Terminalno modificirana rna
JPWO2014098176A1 (ja)	2012-12-21	2017-01-12	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体のアモルファス及びその製造方法
ES2774964T3 (es)	2013-02-04	2020-07-23	Vascular Biogenics Ltd	Métodos para inducir la capacidad de respuesta a un agente antiangiogénico
CA2901226C (fr)	2013-02-18	2020-11-17	Vegenics Pty Limited	Proteines liant le facteur de croissance de l'endothelium vasculaire
US9618523B2 (en)	2013-02-28	2017-04-11	Siemens Healthcare Diagnostics Inc.	Methods and reagents for determining isomeric analytes
KR20150143458A (ko)	2013-03-06	2015-12-23	메리맥 파마슈티컬즈, 인크.	항-C-MET 탠덤 Fc 이중특이적 항체
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
CN105264380B (zh)	2013-05-14	2017-09-05	卫材R&D管理有限公司	用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
EP3052106A4 (fr)	2013-09-30	2017-07-19	ModernaTX, Inc.	Polynucléotides codant des polypeptides de modulation immunitaire
KR20160067219A (ko)	2013-10-03	2016-06-13	모더나 세라퓨틱스, 인코포레이티드	저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
KR102127408B1 (ko) *	2014-01-29	2020-06-29	삼성전자주식회사	항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
TWI558399B (zh)	2014-02-26	2016-11-21	美國禮來大藥廠	癌症之組合療法
TW201622744A (zh)	2014-03-04	2016-07-01	美國禮來大藥廠	癌症之組合療法
CA2949121A1 (fr)	2014-05-15	2015-11-19	Bristol-Myers Squibb Company	Traitement du cancer du poumon a l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancereux
TWI569808B (zh)	2014-08-15	2017-02-11	禮來大藥廠	肝細胞腫瘤（ｈｃｃ）之治療
SMT202200367T1 (it)	2014-08-28	2022-11-18	Eisai R&D Man Co Ltd	Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso
WO2016057726A2 (fr)	2014-10-07	2016-04-14	Kadmon Corporation, Llc	Anticorps humains anti-vegfr-2/kdr
TW201625304A (zh)	2014-10-24	2016-07-16	美國禮來大藥廠	泌尿上皮癌之療法
TWI704151B (zh)	2014-12-22	2020-09-11	美商美國禮來大藥廠	Ｅｒｋ抑制劑
CA2976325C (fr)	2015-02-25	2023-07-04	Eisai R&D Management Co., Ltd.	Procede de suppression de l'amertume d'un derive de quinoleine
KR102662228B1 (ko)	2015-03-04	2024-05-02	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US20180155429A1 (en)	2015-05-28	2018-06-07	Bristol-Myers Squibb Company	Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US11078278B2 (en)	2015-05-29	2021-08-03	Bristol-Myers Squibb Company	Treatment of renal cell carcinoma
TW201711702A (zh)	2015-06-04	2017-04-01	應克隆公司	使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
CN107801379B (zh)	2015-06-16	2021-05-25	卫材R&D管理有限公司	抗癌剂
RS61532B1 (sr)	2015-07-14	2021-04-29	Bristol Myers Squibb Co	Postupak lečenja kancera primenom inhibitora imunološke kontrolne tačke; antitelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
TW201716439A (zh)	2015-07-20	2017-05-16	美國禮來大藥廠	Ｈｅｒ３抗體
AU2016309356B2 (en)	2015-08-20	2021-06-24	Eisai R&D Management Co., Ltd.	Tumor therapeutic agent
KR101896882B1 (ko)	2015-11-30	2018-09-11	앱클론(주)	Vegfr2에 특이적으로 결합하는 항체
TW201736399A (zh) *	2015-12-31	2017-10-16	財團法人生物技術開發中心	抗vegfr抗體及其應用
EP3442573A1 (fr) *	2016-04-15	2019-02-20	Eli Lilly and Company	Utilisation d'une association de ramucirumab et de mérestinib pour le traitement du cancer colorectal
JP2019513767A (ja)	2016-04-15	2019-05-30	イーライリリーアンドカンパニー	マントル細胞リンパ腫の治療における使用のためのラムシルマブ及びアベマシクリブの組み合わせ療法
JP7169195B2 (ja)	2016-05-20	2022-11-10	バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド	癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
JP2019517507A (ja)	2016-06-03	2019-06-24	イムクローンリミテッドライアビリティカンパニー	特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
WO2018069871A2 (fr) *	2016-10-13	2018-04-19	Sorrento Therapeutics, Inc.	Protéines de liaison anti-kras
US20200062850A1 (en)	2016-10-28	2020-02-27	Imclone Llc	Combination of an anti-vegfr-2 antibody and an anti-pd-l1 antibody for the treatment of cancer
AU2017363309A1 (en) *	2016-11-23	2019-07-11	Bioverativ Therapeutics Inc.	Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
US10537637B2 (en)	2017-01-05	2020-01-21	Gensun Biopharma Inc.	Checkpoint regulator antagonists
ES2971448T3 (es)	2017-02-08	2024-06-05	Eisai R&D Man Co Ltd	Composición farmacéutica para el tratamiento de tumores
CN106674349B (zh) *	2017-03-07	2018-03-13	北京东方百泰生物科技有限公司	一种改进的抗vegfr‑2单克隆抗体
CA3061888A1 (fr)	2017-05-16	2018-11-22	Eisai R&D Management Co., Ltd.	Traitement du carcinome hepatocellulaire
WO2019009879A1 (fr) *	2017-07-03	2019-01-10	Development Center For Biotechnology	Anticorps anti-vegfr et ses utilisations
EP3672633A1 (fr)	2017-08-21	2020-07-01	Eli Lilly and Company	Combinaisons d'inhibiteurs d'egfr et d'anticorps anti-vegfr -2 humains
CN111356480A (zh)	2017-10-20	2020-06-30	脉管生物生长有限公司	用于抗血管生成剂疗法的诊断方法
WO2020006516A1 (fr)	2018-06-29	2020-01-02	Gensun Biopharma, Inc.	Antagonistes des régulateurs de points de contrôle immunitaires antitumoraux
CN113056288A (zh)	2018-11-20	2021-06-29	康奈尔大学	放射性核素的大环配合物及其在癌症的放射治疗中的应用
CN111423512B (zh) *	2019-01-10	2024-01-05	北京比洋生物技术有限公司	阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
CA3131936A1 (fr)	2019-03-13	2020-09-17	Vascular Biogenics Ltd.	Procedes de therapie antitumorale
US10851157B2 (en)	2019-07-01	2020-12-01	Gensun Biopharma, Inc.	Antagonists targeting the TGF-β pathway
US12214218B2 (en)	2019-07-31	2025-02-04	Memorial Sloan Kettering Cancer Center	Perfusion modulated tumor dose sculpting with single dose radiotherapy
WO2021076620A1 (fr)	2019-10-15	2021-04-22	Eli Lilly And Company	Lignées cellulaires mammifères déficientes en lipase/estérase modifiées par recombinaison
CN111024949A (zh) *	2019-12-31	2020-04-17	上海博威生物医药有限公司	一种重组抗vegfr2单克隆抗体的生物活性分析方法及其应用
JP2023540490A (ja)	2020-09-02	2023-09-25	ファーマブシンインコーポレイテッド	がん患者を治療するためのｐｄ－１拮抗薬及びｖｅｇｆｒ－２拮抗薬の併用療法
CN114316064B (zh) *	2020-10-10	2024-07-26	广东菲鹏制药股份有限公司	融合蛋白及其应用
JP2024500847A (ja)	2020-12-18	2024-01-10	センチュリーセラピューティクス，インコーポレイテッド	適合可能な受容体特異性を有するキメラ抗原受容体システム
CA3215430A1 (fr) *	2021-04-14	2022-10-20	Suzhou Transcenta Therapeutics Co., Ltd.	Nouveaux anticorps anti-hvegfr2
WO2022256820A1 (fr)	2021-06-03	2022-12-08	Gensun Biopharma Inc.	Antagonistes multispécifiques
WO2023130081A1 (fr)	2021-12-30	2023-07-06	Neoimmunetech, Inc.	Procédé de traitement d'une tumeur avec une combinaison d'une protéine il-7 et d'un antagoniste du vegf
WO2025120867A1 (fr)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et anticorps anti-vegfr2
WO2025121445A1 (fr)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et agents stabilisant ou augmentant l'expression de cldn18.2
WO2025120866A1 (fr)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et agents stabilisant ou augmentant l'expression de cldn18.2
WO2025170315A1 (fr) *	2024-02-05	2025-08-14	주식회사 트리오어	Protéine de fusion comprenant un domaine double fonction et ses utilisations
WO2025184397A1 (fr) *	2024-02-29	2025-09-04	Sonoma Biotherapeutics, Inc.	Récepteurs antigéniques chimériques contenant un domaine inductible par anticorps

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5328695A (en) *	1983-03-22	1994-07-12	Massachusetts Institute Of Technology	Muscle morphogenic protein and use thereof
US4714680B1 (en) *	1984-02-06	1995-06-27	Univ Johns Hopkins	Human stem cells
US4965204A (en) *	1984-02-06	1990-10-23	The Johns Hopkins University	Human stem cells and monoclonal antibodies
US5130144B1 (en) *	1984-02-06	1995-08-15	Univ Johns Hopkins	Human stem cells and monoclonal antibodies
US4683295A (en) *	1984-05-24	1987-07-28	Scripps Clinic And Research Foundation	Method for the preparation of anti-receptor antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
EP0318554B2 (fr)	1987-05-21	2005-01-12	Micromet AG	Proteines mutifonctionnelles a cible predeterminee
US5674722A (en) *	1987-12-11	1997-10-07	Somatix Therapy Corporation	Genetic modification of endothelial cells
AU4128089A (en)	1988-09-15	1990-03-22	Rorer International (Overseas) Inc.	Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US6075181A (en) *	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5061620A (en) *	1990-03-30	1991-10-29	Systemix, Inc.	Human hematopoietic stem cell
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DE4103975A1 (de)	1991-02-09	1992-08-13	Thomson Brandt Gmbh	Verfahren zur verkuerzung der zugriffszeit
ES2204890T3 (es) *	1991-03-06	2004-05-01	Merck Patent Gmbh	Anticuerpos monoclonales humanizados.
US5543503A (en) *	1991-03-29	1996-08-06	Genentech Inc.	Antibodies to human IL-8 type A receptor
US20010021382A1 (en) *	1991-03-29	2001-09-13	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
US5367057A (en) *	1991-04-02	1994-11-22	The Trustees Of Princeton University	Tyrosine kinase receptor flk-2 and fragments thereof
DE69233745D1 (de)	1991-12-02	2008-10-23	Cambridge Antibody Tech	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5861301A (en) *	1992-02-20	1999-01-19	American Cayanamid Company	Recombinant kinase insert domain containing receptor and gene encoding same
DE69332948T2 (de) *	1992-03-05	2003-11-27	Board Of Regents, The University Of Texas System	Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
US5928947A (en) *	1992-07-27	1999-07-27	California Institute Of Technology	Mammalian multipotent neural stem cells
US5981569A (en) *	1992-11-13	1999-11-09	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
ATE199392T1 (de) *	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
JP3670302B2 (ja) *	1993-07-23	2005-07-13	ファナック株式会社	射出成形機における可塑化の管理方法
US5599703A (en) *	1993-10-28	1997-02-04	The United States Of America As Represented By The Secretary Of The Navy	In vitro amplification/expansion of CD34+ stem and progenitor cells
US5840299A (en) *	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
US20030108545A1 (en) *	1994-02-10	2003-06-12	Patricia Rockwell	Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) *	1994-02-10	2004-11-02	Imclone Systems Incorporated	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5861499A (en)	1994-02-10	1999-01-19	Imclone Systems Incorporated	Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
AT402796B (de) *	1995-02-01	1997-08-25	Fritschi Apparatebau	Schibindung
US5843633A (en) *	1996-04-26	1998-12-01	Amcell Corporation	Characterization of a human hematopoietic progenitor cell antigen
JP3658471B2 (ja) *	1996-09-30	2005-06-08	株式会社日立製作所	電子ショッピングシステムにおける買物かご機能の提示方法及び電子ショッピングシステム
US6986890B1 (en) *	1996-11-21	2006-01-17	Kyowa Hakko Kogyo Co., Ltd.	Anti-human VEGF receptor Flt-1 monoclonal antibody
ATE331806T1 (de) *	1996-11-21	2006-07-15	Kyowa Hakko Kogyo Kk	Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper.
EP1009814B1 (fr) *	1997-06-18	2007-08-29	Merck & Co., Inc. (a New Jersey corp.)	Tyrosine kinase receptrice, kdr
AU9484398A (en) *	1997-09-17	1999-04-05	Genentech Inc.	Promotion or inhibition of angiogenesis and cardiovascularization
AU4079999A (en)	1998-05-15	1999-12-06	Imclone Systems Incorporated	Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US20020172678A1 (en) *	2000-06-23	2002-11-21	Napoleone Ferrara	EG-VEGF nucleic acids and polypeptides and methods of use
GB9824579D0 (en) *	1998-11-10	1999-01-06	Novartis Ag	Organic compounds
DE60032459D1 (de) *	1999-01-15	2007-02-01	Medstar Res Inst	Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1
WO2000044777A1 (fr)	1999-01-29	2000-08-03	Imclone Systems Incorporated	Anticorps specifiques au kdr et leurs utilisations
US6245759B1 (en) *	1999-03-11	2001-06-12	Merck & Co., Inc.	Tyrosine kinase inhibitors
US6297238B1 (en) *	1999-04-06	2001-10-02	Basf Aktiengesellschaft	Therapeutic agents
US6703020B1 (en) *	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
WO2000064946A2 (fr) *	1999-04-28	2000-11-02	Board Of Regents, The University Of Texas System	Compositions et procedes de traitement du cancer par inhibition selective de vegf
US7740841B1 (en)	2000-01-28	2010-06-22	Sunnybrook Health Science Center	Therapeutic method for reducing angiogenesis
KR20020087453A (ko)	2000-03-31	2002-11-22	임클론 시스템즈 인코포레이티드	혈관 내피 성장 인자 수용체 길항제를 사용한, 포유동물의비충실성 종양의 치료 방법
WO2001090192A2 (fr)	2000-05-24	2001-11-29	Imclone Systems Incorporated	Proteines bispecifiques de liaison a l'antigene du type immunoglobulines, et procede de production correspondant
AU2002316305A1 (en)	2001-06-20	2003-01-08	Vlaams Interuniversitair Institut Voor Biotechnologie	Method of treating atherosclerosis and other inflammatory diseases
JP2005518336A (ja)	2001-06-26	2005-06-23	イムクローンシステムズインコーポレイティド	Ｖｅｇｆ受容体に結合する二重特異性抗体
US6519852B1 (en) *	2001-07-26	2003-02-18	Yuecom Manufacturing Co., Ltd.	Method of manufacturing an aluminum alloy wheel rim
DE60333554D1 (de) *	2002-03-04	2010-09-09	Imclone Llc	Kdr-spezifische humane antikörper und deren anwendung
US6844779B2 (en) *	2003-06-19	2005-01-18	The United States Of America As Represented By The Secretary Of The Air Force	Optically isolated bias control circuit

2003
- 2003-03-04 DE DE60333554T patent/DE60333554D1/de not_active Expired - Lifetime
- 2003-03-04 ES ES03711375T patent/ES2347543T3/es not_active Expired - Lifetime
- 2003-03-04 PT PT03711375T patent/PT1487856E/pt unknown
- 2003-03-04 ES ES07023361T patent/ES2362931T3/es not_active Expired - Lifetime
- 2003-03-04 AT AT03711375T patent/ATE475431T1/de active
- 2003-03-04 CA CA2478169A patent/CA2478169C/fr not_active Expired - Lifetime
- 2003-03-04 EP EP10183791A patent/EP2298346A3/fr not_active Withdrawn
- 2003-03-04 EP EP07023361A patent/EP1916001B1/fr not_active Expired - Lifetime
- 2003-03-04 JP JP2003574116A patent/JP2005526506A/ja active Pending
- 2003-03-04 DK DK07023361.4T patent/DK1916001T3/da active
- 2003-03-04 SI SI200331888T patent/SI1487856T1/sl unknown
- 2003-03-04 WO PCT/US2003/006459 patent/WO2003075840A2/fr not_active Ceased
- 2003-03-04 AU AU2003213687A patent/AU2003213687A1/en not_active Abandoned
- 2003-03-04 US US10/506,997 patent/US7498414B2/en active Active
- 2003-03-04 SI SI200332035T patent/SI1916001T1/sl unknown
- 2003-03-04 DK DK03711375.0T patent/DK1487856T3/da active
- 2003-03-04 AT AT07023361T patent/ATE510561T1/de active
- 2003-03-04 PT PT07023361T patent/PT1916001E/pt unknown
- 2003-03-04 EP EP03711375A patent/EP1487856B1/fr not_active Expired - Lifetime
2008
- 2008-09-19 US US12/234,203 patent/US8057791B2/en not_active Expired - Lifetime
2009
- 2009-03-26 JP JP2009076394A patent/JP4970483B2/ja not_active Expired - Lifetime
2010
- 2010-08-30 CY CY20101100793T patent/CY1111141T1/el unknown
2011
- 2011-06-29 CY CY20111100630T patent/CY1111629T1/el unknown
2012
- 2012-02-23 JP JP2012036968A patent/JP5476404B2/ja not_active Expired - Lifetime
2015
- 2015-04-28 HU HUS1500025C patent/HUS1500025I1/hu unknown
- 2015-04-30 CY CY2015018C patent/CY2015018I1/el unknown
- 2015-05-06 FR FR15C0034C patent/FR15C0034I2/fr active Active
- 2015-05-06 LU LU92710C patent/LU92710I2/fr unknown
- 2015-05-06 BE BE2015C027C patent/BE2015C027I2/fr unknown

Also Published As

Publication number	Publication date
HUS1500025I1 (hu)	2017-04-28
SI1487856T1 (sl)	2010-12-31
ATE475431T1 (de)	2010-08-15
US7498414B2 (en)	2009-03-03
CY2015018I2 (el)	2016-04-13
US20090142358A1 (en)	2009-06-04
CY2015018I1 (el)	2016-04-13
PT1916001E (pt)	2011-07-18
ES2347543T3 (es)	2010-11-02
AU2003213687A1 (en)	2003-09-22
EP2298346A2 (fr)	2011-03-23
LU92710I2 (fr)	2015-11-02
CA2478169A1 (fr)	2003-09-18
WO2003075840A2 (fr)	2003-09-18
JP2012105667A (ja)	2012-06-07
HK1118229A1 (en)	2009-02-06
EP2298346A3 (fr)	2011-11-16
DE60333554D1 (de)	2010-09-09
EP1487856A4 (fr)	2006-08-23
ATE510561T1 (de)	2011-06-15
WO2003075840A3 (fr)	2004-04-29
CY1111141T1 (el)	2015-06-11
DK1916001T3 (da)	2011-07-18
JP2009148298A (ja)	2009-07-09
FR15C0034I1 (fr)	2015-06-26
JP5476404B2 (ja)	2014-04-23
EP1916001A3 (fr)	2008-08-13
FR15C0034I2 (fr)	2016-08-26
AU2003213687A8 (en)	2003-09-22
PT1487856E (pt)	2010-09-29
CA2478169C (fr)	2013-04-16
EP1916001A2 (fr)	2008-04-30
JP2005526506A (ja)	2005-09-08
EP1487856B1 (fr)	2010-07-28
EP1916001B1 (fr)	2011-05-25
US20050234225A1 (en)	2005-10-20
CY1111629T1 (el)	2015-10-07
ES2362931T3 (es)	2011-07-15
SI1916001T1 (sl)	2011-10-28
JP4970483B2 (ja)	2012-07-04
DK1487856T3 (da)	2010-10-18
US8057791B2 (en)	2011-11-15
EP1487856A2 (fr)	2004-12-22

Publication	Publication Date	Title
BE2015C027I2 (fr)	2022-05-19
CY1113037T1 (el)	2016-04-13	Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
CY1112993T1 (el)	2016-04-13	Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
DK1565489T3 (da)	2011-03-07	Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
EA202092847A1 (ru)	2021-04-20	Антитела к cd3 и их применение
ATE476992T1 (de)	2010-08-15	Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
NO2017032I1 (no)	2017-07-07	bezlotoksumab
CY1115321T1 (el)	2017-01-04	Αντισωματα κατευθυνομενα προς αγγειοποιητινη-1 και αγγειοποιητινη-2 και χρηση αυτων
NZ591056A (en)	2013-02-22	Human cytomegalovirus neutralizing antibodies and use thereof
SA520411849B1 (ar)	2023-12-17	أجسام مضادة ومتقارنات جسم مضاد مع عقار نوعية من أجل cd123 واستخداماتها
MX2023000738A (es)	2023-02-13	Proteinas de union a antigeno que activan el receptor de leptina.
EP1629084A4 (fr)	2008-01-16	Modulation de l'expression de la proteine c-reactive
MY156315A (en)	2016-02-15	Anti-vegf antibodies
NO20082905L (no)	2008-09-03	Anti-IL-17 antistoff
DK1706424T3 (da)	2009-11-02	FC-region varianter
ATE545657T1 (de)	2012-03-15	Tgf-beta antikörper
ATE395082T1 (de)	2008-05-15	Antikörper gegen krebsantigen tmeff2 und seine anwendungen
WO2008085878A3 (fr)	2009-02-26	Anticorps à haute affinité neutralisant l'entérotoxine staphylococcique
ATE378353T1 (de)	2007-11-15	Neurotrophe faktoren
MX2007004247A (es)	2007-06-12	Agentes de aglutinacion especifica a angiopoyetina-2.
MX2016011177A (es)	2016-12-16	Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
CL2011000911A1 (es)	2012-02-03	Composicion que comprende uno o mas antigenos, un solo dominio variable de inmunoglobulina antiproteina dc-sign y un vehiculo; metodo de elaboracion; y uso para el tratamiento de un tumor.